Company intelligence / Profile preview

REDNVIA

Songdo, Incheon, South Korearednvia.com ↗

Ownership: Private
Development stage: Preclinical

Overview

REDNVIA’s lead asset RNV-1001 (repurposed Evogliptin) for CAVD has advanced to a large Phase II/III trial enrolling 867 patients across the US and Canada. The drug bypassed Phase I due to an established safety profile from its use as an antidiabetic agent. Commercial manufacturing capacity has been secured in Korea. No topline efficacy results have been published yet.

Therapeutic areas: EndocrinologyCardiovascular
Modalities: Small molecules (notably DPP-4 inhibitors such as Evogliptin)
Industry: Biotech

Drug pipeline

3 assets

RNV-1002

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

MOUs with global contract sales organizations including IQVIAmanufacturing partnership with ST Pharm and Dong-A ST for API and final product production

Beyond the preview

Go deeper on REDNVIA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REDNVIA.

Explore the full profile